Compare · NVO vs ROIV
NVO vs ROIV
Side-by-side comparison of Novo Nordisk A/S (NVO) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 9.0x ROIV ($24.82B).
- Over the past year, NVO is down 21.8% and ROIV is up 201.6% - ROIV leads by 223.4 points.
- ROIV has been more active in the news (14 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- Novo Nordisk A/S
- Roivant Sciences Ltd.
- Price
- $50.31-2.25%
- $34.50+1.65%
- Market cap
- $222.81B
- $24.82B
- 1M return
- +15.47%
- +13.47%
- 1Y return
- -21.78%
- +201.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 18
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ROIV
- CEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)
- Director Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)
- President and Vant Chair Torti Frank covered exercise/tax liability with 40,310 shares, decreasing direct ownership by 0.30% to 13,536,202 units (SEC Form 4) to cover withholding tax
- President & CIO Sukhatme Mayukh covered exercise/tax liability with 46,878 shares, decreasing direct ownership by 0.25% to 18,630,739 units (SEC Form 4) to satisfy tax liability
- Director Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46 (SEC Form 4)
- Director Manchester Keith S sold $56,444,076 worth of shares (1,638,163 units at $34.46), decreasing direct ownership by 10% to 1,748,403 units (SEC Form 4)
- Director Gold Daniel Allen sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- Director by Deputization Qvt Financial Lp sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- SEC Form 144 filed by Roivant Sciences Ltd.
- SEC Form 144 filed by Roivant Sciences Ltd.